Tags

Type your tag names separated by a space and hit enter

Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren's syndrome: a retrospective clinical study.
J Rheumatol 2011; 38(10):2198-208JR

Abstract

OBJECTIVE

To retrospectively analyze the clinical course of patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma of the parotid gland and associated Sjögren's syndrome (SS).

METHODS

All consecutive patients with SS and MALT lymphoma (MALT-SS) diagnosed in the University Medical Center Groningen between January 1997 and January 2009 were analyzed. Clinical course and treatment outcome of SS and MALT lymphoma were evaluated.

RESULTS

From a total of 329 patients with SS, 35 MALT-SS patients were identified, with a median followup of 76 months (range 16-153 mo). MALT lymphoma was localized in the parotid gland in all cases. Treatment consisted of "watchful waiting" (n = 10), surgery (n = 3), radiotherapy (n = 1), surgery combined with radiotherapy (n = 2), rituximab only (n = 13), or rituximab combined with chemotherapy (n = 6). Complete response was observed in 14 patients, partial response in 1 patient, and stable disease in 20 patients. In 6 of 7 patients with initially high SS disease activity (M-protein, cryoglobulins, IgM rheumatoid factor > 100 KIU/l, severe extraglandular manifestations), MALT lymphoma progressed and/or SS disease activity increased after a median followup of 39 months (range 4-98 mo), necessitating retreatment. Only 1 patient with MALT who had low SS disease activity showed progression of lymphoma when left untreated.

CONCLUSION

An initially high SS disease activity likely constitutes an adverse prognostic factor for progression of lymphoma and/or SS. Such patients may require treatment for both MALT lymphoma and SS. In SS patients with localized asymptomatic MALT lymphoma and low SS disease activity, a "watchful waiting" strategy seems justified.

Authors+Show Affiliations

Department of Hematology, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21844152

Citation

Pollard, Rodney P E., et al. "Treatment of Mucosa-associated Lymphoid Tissue Lymphoma in Sjogren's Syndrome: a Retrospective Clinical Study." The Journal of Rheumatology, vol. 38, no. 10, 2011, pp. 2198-208.
Pollard RP, Pijpe J, Bootsma H, et al. Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren's syndrome: a retrospective clinical study. J Rheumatol. 2011;38(10):2198-208.
Pollard, R. P., Pijpe, J., Bootsma, H., Spijkervet, F. K., Kluin, P. M., Roodenburg, J. L., ... van Imhoff, G. W. (2011). Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren's syndrome: a retrospective clinical study. The Journal of Rheumatology, 38(10), pp. 2198-208. doi:10.3899/jrheum.110077.
Pollard RP, et al. Treatment of Mucosa-associated Lymphoid Tissue Lymphoma in Sjogren's Syndrome: a Retrospective Clinical Study. J Rheumatol. 2011;38(10):2198-208. PubMed PMID: 21844152.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren's syndrome: a retrospective clinical study. AU - Pollard,Rodney P E, AU - Pijpe,Justin, AU - Bootsma,Hendrika, AU - Spijkervet,Fred K L, AU - Kluin,Philip M, AU - Roodenburg,Jan L N, AU - Kallenberg,Cees G M, AU - Vissink,Arjan, AU - van Imhoff,Gustaaf W, Y1 - 2011/08/15/ PY - 2011/8/17/entrez PY - 2011/8/17/pubmed PY - 2012/2/11/medline SP - 2198 EP - 208 JF - The Journal of rheumatology JO - J. Rheumatol. VL - 38 IS - 10 N2 - OBJECTIVE: To retrospectively analyze the clinical course of patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma of the parotid gland and associated Sjögren's syndrome (SS). METHODS: All consecutive patients with SS and MALT lymphoma (MALT-SS) diagnosed in the University Medical Center Groningen between January 1997 and January 2009 were analyzed. Clinical course and treatment outcome of SS and MALT lymphoma were evaluated. RESULTS: From a total of 329 patients with SS, 35 MALT-SS patients were identified, with a median followup of 76 months (range 16-153 mo). MALT lymphoma was localized in the parotid gland in all cases. Treatment consisted of "watchful waiting" (n = 10), surgery (n = 3), radiotherapy (n = 1), surgery combined with radiotherapy (n = 2), rituximab only (n = 13), or rituximab combined with chemotherapy (n = 6). Complete response was observed in 14 patients, partial response in 1 patient, and stable disease in 20 patients. In 6 of 7 patients with initially high SS disease activity (M-protein, cryoglobulins, IgM rheumatoid factor > 100 KIU/l, severe extraglandular manifestations), MALT lymphoma progressed and/or SS disease activity increased after a median followup of 39 months (range 4-98 mo), necessitating retreatment. Only 1 patient with MALT who had low SS disease activity showed progression of lymphoma when left untreated. CONCLUSION: An initially high SS disease activity likely constitutes an adverse prognostic factor for progression of lymphoma and/or SS. Such patients may require treatment for both MALT lymphoma and SS. In SS patients with localized asymptomatic MALT lymphoma and low SS disease activity, a "watchful waiting" strategy seems justified. SN - 0315-162X UR - https://www.unboundmedicine.com/medline/citation/21844152/Treatment_of_mucosa_associated_lymphoid_tissue_lymphoma_in_Sjogren's_syndrome:_a_retrospective_clinical_study_ L2 - http://www.jrheum.org/cgi/pmidlookup?view=long&pmid=21844152 DB - PRIME DP - Unbound Medicine ER -